文献速递中枢神经肿瘤放疗放疗物理与技术

13次立体定向放疗期间脑转移瘤的靶区间期变化

Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy.
PubMed 文献 · Radiat Oncol · 2021-07-28

回顾性分析23例患者27个脑转移病灶接受13次SRT的靶区间期变化,中位初始GTV为3.8 cm³,SRT开始至中期MRI中位6天。近三分之一病灶中期GTV较初始GTV变化超过20%,超过半数病灶中期GTV与初始PTV不完全重叠,提示分次增加时应考虑评估靶区变化并考虑自适应放疗。

要点

  • 13次SRT期间近三分之一脑转移病灶GTV变化超过20%。
  • 超过半数病灶中期GTV与初始PTV不完全重叠。
  • 分次增加时建议评估靶区体积与位置变化并考虑自适应放疗。

核心结论

  • 与初始GTV相比,近三分之一接受13次SRT的脑转移病灶中期GTV变化超过20%。

研究设计与样本

  • 回顾性分析23例患者27个脑转移病灶,均接受13次动态适形弧SRT,PTV处方周边剂量39-44.2 Gy/13次。

主要发现

  • 中位初始GTV为3.8 cm³,SRT开始至中期MRI中位时间为6天。
  • 5个病灶中期GTV较初始GTV增加超过20%,5个病灶减少超过20%。
  • GTV变化超过20%与原发疾病或囊性/坏死成分存在无显著关联。
  • 超过半数病灶的中期GTV与初始PTV不完全重叠。

临床怎么用

  • SRT分次数增加时,应评估靶区体积和位置变化并考虑自适应放疗。

局限性

  • 回顾性研究,样本量较小(23例患者27个病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17 days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT. METHODS: Our analyses included data from 23 patients and 27 metastatic brain lesions treated with 13-fraction SRT with dynamic conformal arc therapy. The peripheral dose prescribed to the planning target volume (PTV) was 39-44.2 Gy in 13-fractions. The gross tumor volume (GTV) of the initial SRT plan (initial GTV), initial PTV, and modified GTV based on the mid-treatment MRI scan (mid-treatment GTV) were assessed. RESULTS: The median initial GTV was 3.8 cm3 and the median time from SRT initiation to the mid-treatment MRI scan was 6 days. Compared to the initial GTV, the mid-treatment GTV increased by more than 20% in five lesions and decreased by more than 20% in five lesions. Interfractional GTV volume changes of more than 20% were not significantly associated with primary disease or the presence of cystic components/necrosis. The mid-treatment GTV did not overlap perfectly with the initial PTV in more than half of the lesions. CONCLUSIONS: Compared to the initial GTV, the mid-treatment GTV changed by more than 20% in almost one-third of lesions treated with 13-fraction SRT. As SRT usually generates a steep dose gradient as well as increasing the maximum dose of PTV compared to conventional radiotherapy, assessment of the volume and locational target changes and adaptive radiotherapy should be considered as the number of fractions increases.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Uto M, Ogura K, Katagiri T, et al. Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy. Radiat Oncol. 2021. PMID: 34321033. doi:10.1186/s13014-021-01869-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。